InCephalo is a preclinical stage biotech company founded in May 2021. InCephalo's six (6) founders with various backgrounds came together with the vision of making a difference in the lives of those being diagnosed with brain cancer. The founders experienced first-hand what it means if someone important to them gets diagnosed with this disease. The founding team has complementary competencies and consists of academics, a neurosurgeon, a legal expert, and a biotech entrepreneur. Since its foundation, the company convinced world-renown neurosurgeons, neuro-oncologists, preclinical, clinical, and regulatory experts to join them.
The company focuses on developing antibodies and other biological treatments for the local treatment of CNS cancers. Its primary drug candidate recieved EMA ODD.
The company focuses on developing antibodies and other biological treatments for the local treatment of CNS cancers. Its primary drug candidate recieved EMA ODD.
Investors 2
| Date | Name | Website |
| 09.11.2022 | VentureLab | venturelab... |
| - | High-Tech ... | htgf.de |
Mentions in press and media 8
| Date | Title | Description |
| 31.03.2025 | BioEntrepreneurship: Catalyzing innovation from Lab to market | Swiss universities are innovation hubs, where novel ideas are born with the potential to address critical global challenges. Yet, without the right support, many of these promising concepts remain confined to the lab. The Institute of Rege... |
| 08.11.2024 | Bio-Europe: Switzerland's Biotech Showcase in Stockholm | The heart of Europe beats strong in Stockholm this November. Bio-Europe, the continent's premier partnering event for the life sciences, is back for its 30th edition. This year, it promises to be a melting pot of innovation, collaboration, ... |
| 05.11.2024 | Bio Europe in Stockholm hosts 33 Swiss companies | Currently in its 30-year-edition, BIO-Europe remains Europe's leading partnering event, for the life sciences ecosystem, providing an exceptional opportunity to explore the latest trends learn and connect with potential partners. The past ... |
| 28.03.2024 | New additions to startups’ board of directors | Trevor Hawkins joins Resistell’s Board of Directors, bringing 25 years of experience from his leadership roles across research, clinical, and corporate spheres globally. He has held several senior executive roles at Siemens Healthcare, Phi... |
| 06.11.2023 | A decent representation at BIO-Europe | |
| 13.10.2023 | International grants fuel medical and sustainable solutions | |
| 05.06.2023 | A significant number of Swiss biotechs exhibit in Boston | |
| 21.07.2022 | Ten Biotech startups brace for Boston |